Agios Pharmaceuticals, Inc. - AGIO STOCK NEWS

Agios Pharmaceuticals reported $3.1 million in U.S. net revenue for PYRUKYND® in Q2 2022, marking its first full quarter of sales post-FDA approval. The company announced a leadership transition with Brian Goff becoming CEO on August 8, 2022, succeeding Jackie Fouse, who will serve as Chair of the Board. Agios has $1.1 billion in cash and marketable securities as of June 30, 2022, supporting its growth strategy. The company is enrolling patients in five pivotal studies for PYRUKYND® in various blood disorders, aiming for significant milestones by year-end.

Agios Pharmaceuticals (NASDAQ: AGIO) announced a conference call scheduled for August 4, 2022, at 8:00 a.m. ET, to discuss its Q2 2022 financial results and business updates. Investors can access the live webcast on the company's website, with an archived version available post-event. Agios focuses on therapies for genetically defined diseases and markets a first-in-class pyruvate kinase activator for PK deficiency. The company is also advancing multiple investigational medicines targeting various disorders including sickle cell disease and MDS-associated anemia.

Agios Pharmaceuticals (NASDAQ: AGIO) announced leadership changes effective August 8, 2022, with Jackie Fouse transitioning from CEO to Chair of the Board and Brian Goff appointed as the new CEO. Fouse highlighted Agios's success in divesting its oncology portfolio, launching its first genetically defined disease medicine, and initiating pivotal clinical trials. Goff comes with over 30 years of biopharmaceutical experience and aims to advance therapies for rare diseases, leveraging Agios's strong pipeline. This leadership transition is seen as a strategic move to enhance focus on genetically defined diseases.

Agios Pharmaceuticals (NASDAQ: AGIO) recently shared positive results from its Phase 3 ACTIVATE study and extension studies for PYRUKYND® (mitapivat) in treating adult patients with pyruvate kinase deficiency (PK deficiency). Approximately 36% of treated patients achieved normal hemoglobin levels at least once. Patients reported significant improvements in PK deficiency symptoms including jaundice and fatigue. The therapy, which received FDA approval in February 2022, is also under review by the EMA. Agios is focused on enhancing treatment strategies and managing the complications associated with PK deficiency.

Agios Pharmaceuticals (NASDAQ: AGIO) announced a leadership transition as Sarah Gheuens, M.D., Ph.D., will become Head of R&D and Chief Medical Officer, while Bruce Car, Ph.D., steps down. The company will focus on late lead-optimization programs and aims to save $40-50 million annually starting in 2023. This evolution prioritizes sustainable pipeline growth and strategic in-licensing of promising assets. Agios expects its cash reserves will support its operations and growth without needing additional equity financing.

Agios Pharmaceuticals will present new patient-reported outcomes from its ACTIVATE Phase 3 Study of PYRUKYND (mitapivat) in adults with pyruvate kinase deficiency at the European Hematology Association Annual Congress from June 9-12, 2022. Key highlights include long-term normalization of hemoglobin levels and reduced transfusion needs. Additional data from the ESTIMATE Phase 2 Study in sickle cell disease will also be shared. An investor webcast is set for June 13, 2022, at 8 a.m. ET to review selected data.

Agios Pharmaceuticals (NASDAQ: AGIO) is set to present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022, at 10:30 a.m. ET. The presentation will focus on Agios's pioneering work in therapies for genetically defined diseases and its leadership in cellular metabolism. A live webcast can be accessed via their website, with an archived replay available for two weeks. Agios develops treatments for conditions like pyruvate kinase deficiency, with a strong clinical pipeline addressing thalassemia, sickle cell disease, and more.

Agios Pharmaceuticals (NASDAQ: AGIO) has received FDA approval for PYRUKYND®, the first therapy for hemolytic anemia in adults with pyruvate kinase deficiency. The commercial launch is underway, generating approximately $0.8 million in net revenue in Q1 2022. The company has a cash position of $1.2 billion, enabling continued operations and R&D activities. Notable milestones for 2022 include additional clinical studies in thalassemia and sickle cell disease, as well as pediatric trials for PK deficiency. The net loss from continuing operations was $94.8 million in Q1 2022.

Agios Pharmaceuticals (NASDAQ: AGIO) will host a conference call on May 5, 2022, at 8:00 a.m. ET to discuss its Q1 2022 financial results and business highlights. Investors can access the live webcast on Agios's website, with a replay available two hours post-event. The company focuses on genetically defined diseases and has developed a first-in-class pyruvate kinase activator for PK deficiency. Agios is advancing a clinical pipeline targeting alpha- and beta-thalassemia, sickle cell disease, and more.